-Amarin’s EPA medicine called Vascepa recently showed a 25% relative risk reduction in newly announced data from a CardioVascular Outcomes Trial.
-Today I breakdown the results and talk about how it compares to other CVOT data and whether Amarin is likely to rival companies with a LDL-c lowering drug pipelines.
Relevant links:
http://investor.amarincorp.com/node/15741/pdf
http://investor.amarincorp.com/system/files-encrypted/nasdaq_kms/assets/2018/09/27/10-23-58/AMRN%20Investor%20Deck%20Sept%20Post%20R-IT%20v3.pdf
https://www.ncbi.nlm.nih.gov/pubmed/29935936
*this is not investment/trading advice*
Follow me @matthewlepoire
Advertisements
